welcome
Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey

Health

Health

Cantor Maintains PriceTarget on BMY, Eyes Alzheimer’s Trial as Key Catalyst

Insider Trading & Hedge Fund Data, and Investment Newsletter From Insider Monkey
Summary
Nutrition label

82% Informative

Cantor Fitzgerald maintained its price target of $ 55 and its rating of Neutral for Bristol-Myers Squibb Company ( NYSE : BMY ) Cobenfy ’s ADEPT-2 top-line data is anticipated in 2025 , possibly as early as the second half of that year.

Cantor Fitzgerald characterized ADEPt-2 as “challenging to handicap” because of the varied older group being treated, the lack of clinical data.

VR Score

79

Informative language

76

Neutral language

65

Article tone

formal

Language

English

Language complexity

69

Offensive language

not offensive

Hate speech

not hateful

Attention-grabbing headline

not detected

Known propaganda techniques

not detected

Time-value

medium-lived

Source diversity

1

Affiliate links

no affiliate links